Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2022 Apr 28;28(5):1097. doi: 10.1038/s41591-022-01827-x

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Irene Ganan-Gomez 1, Hui Yang 1, Feiyang Ma 2,3, Guillermo Montalban-Bravo 1, Natthakan Thongon 1, Valentina Marchica 4, Guillaume Richard-Carpentier 1, Kelly Chien 1, Ganiraju Manyam 5, Feng Wang 6, Ana Alfonso 1, Shuaitong Chen 1, Caleb Class 7, Rashmi Kanagal-Shamanna 8, Justin P Ingram 9, Yamini Ogoti 1, Ashley Rose 1, Sanam Loghavi 8, Pamela Lockyer 1, Benedetta Cambo 4, Muharrem Muftuoglu 1, Sarah Schneider 10, Vera Adema 1, Michael McLellan 11, John Garza 11, Matteo Marchesini 1,12, Nicola Giuliani 4, Matteo Pellegrini 2, Jing Wang 5, Jason Walker 11, Ziyi Li 7, Koichi Takahashi 1, Joel D Leverson 9, Carlos Bueso-Ramos 8, Michael Andreeff 1, Karen Clise-Dwyer 10, Guillermo Garcia-Manero 1, Simona Colla 1,
PMCID: PMC9117132  PMID: 35484266

Correction to: Nature Medicine 10.1038/s41591-022-01696-4, published online 3 March 2022.

In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.


Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES